GleamWall
中文EN

CRIS CURIS INC

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1108205 · Fiscal year ends 12/31

Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-36.9%
TTM net income YoY49.8%
TTM EPS YoY90.5%
Revenue 3-yr CAGR-12.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-100.2%
Net margin-299.7%
FCF margin—
EBITDA margin-98.5%

Returns

ROE-693.9%
ROA-61.3%
ROIC (approx.)—
Asset turnover0.20x

Leverage & solvency

Liabilities / assets57.2%
Debt / equity0.00x
Current ratio1.11x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.37x
Accruals ratio22.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue—$0$0$1.14M$3.18M$2.75M$2.38M$3.35M
R&D expense$5.59M$6.71M$6.45M$5.83M$6.43M$7.46M$8.54M$8.97M
SG&A expense$3.15M$3.23M$5.07M$2.88M$3.65M$3.53M$3.98M$3.35M
Operating income-$8.75M-$9.94M-$11.52M$19.62M-$6.92M-$8.25M-$10.16M-$8.99M
Net income-$8.12M-$8.58M-$24.20M$19.36M-$7.73M-$8.59M-$10.62M-$9.62M
EBITDA-$8.74M-$9.93M-$11.51M$19.66M-$6.89M-$8.21M-$10.10M-$8.98M
EPS (basic)-1.94-4.02-1.25—-9.86-13.61-1.25—
EPS (diluted)-1.94-4.02-1.25—-9.86-13.61-1.25—
Weighted avg. shares (diluted)4.18M2.14M19.36M—784,109631,4758.49M—
Balance sheet
Cash & equivalents$5.01M$5.07M$15.00M$5.06M$9.05M$10.14M$20.28M$20.54M
Short-term investments———————$0
Receivables———$0$3.24M$2.75M$2.31M$3.35M
Current assets$6.92M$6.72M$16.61M$6.92M$13.91M$14.42M$24.81M$26.39M
PP&E, net$36,000$46,000$54,000$62,000$98,000$130,000$172,000$231,000
Goodwill$8.98M$8.98M$8.98M$8.98M$8.98M$8.98M$8.98M$8.98M
Total assets$18.80M$18.97M$29.69M$19.97M$27.64M$29.23M$39.33M$41.27M
Current liabilities$16.25M$13.68M$14.97M$14.08M$19.91M$19.37M$20.12M$19.03M
Short-term debt———$0$6.95M$7.35M$7.23M$7.56M
Total liabilities$16.25M$14.28M$16.98M$14.50M$42.33M$43.22M$45.93M$47.26M
Shareholders' equity$2.55M$4.70M$12.71M$5.46M-$14.69M-$13.99M-$6.61M-$6.00M
Shares outstanding4.10M1.95M39.98M646,53712.73M10.71M10.46M8.49M
Cash flow statement
Operating cash flow-$5.75M-$9.65M-$9.00M-$6.37M-$5.57M-$8.01M-$7.25M-$9.26M
Investing cash flow—$0$0$2.50M$0$0$0-$428,000
Financing cash flow$5.69M-$282,000$18.94M-$119,000$4.48M-$2.13M$7.54M$8.83M
Depreciation & amortization$10,000$8,000$8,000$36,000$32,000$42,000$59,000$16,000
Stock-based compensation$526,000$569,000$575,000$795,000$924,000$1.14M$1.16M$1.28M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.